These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 2730685)

  • 1. A novel effect of pargyline on cholinergic catecholamine secretion.
    Dry KL; Dart AM; Phillips JH
    Biochem Pharmacol; 1989 May; 38(10):1699-702. PubMed ID: 2730685
    [No Abstract]   [Full Text] [Related]  

  • 2. Catecholamine metabolism in pargyline treated rats exposed to stress.
    Prasad R; Patel V; Chansouria JP; Udupa KN
    Endocrinol Exp; 1980; 14(2):147-50. PubMed ID: 6104592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of harmaline on the ability of pargyline to alter catecholamine metabolism in rats.
    Fuller RW; Hemrick-Luecke SK; Perry KW
    Biochem Pharmacol; 1981 Jun; 30(11):1295-8. PubMed ID: 7271828
    [No Abstract]   [Full Text] [Related]  

  • 4. Application of steady-state kinetics to the study of catecholamine turnover after monoamine oxidase inhibition or reserpine administration.
    Neff NH; Costa E
    J Pharmacol Exp Ther; 1968 Mar; 160(1):40-7. PubMed ID: 5639109
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of monoamine oxidase inhibition on catecholamine levels: evidence for synthesis but not storage of epinephrine in rat spinal cord.
    Sved AF
    Brain Res; 1990 Apr; 512(2):253-8. PubMed ID: 2354362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Choline stimulates nicotinic receptors on adrenal medullary chromaffin cells to induce catecholamine secretion.
    Holz RW; Senter RA
    Science; 1981 Oct; 214(4519):466-8. PubMed ID: 7291988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of lordosis behavior by intrahypothalamic implants of pargyline.
    Luine VN; Fischette CT
    Neuroendocrinology; 1982 Apr; 34(4):237-44. PubMed ID: 7070593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Catecholamine degradation by monoamine oxidase in locus coeruleus neurons of the rat. An immunohistochemical study.
    Kishimoto Y; Geffard M; Arai R
    Brain Res; 2000 Mar; 859(2):373-7. PubMed ID: 10719089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of antibiotics on the binding of pargyline to monoamine oxidase in cultured hepatocytes.
    Mayne AM; Evans PJ
    Biochem Pharmacol; 1988 Jul; 37(14):2823-32. PubMed ID: 3395359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of catecholamine inactivation by the endocrine pancreas.
    Feldman JM; Chapman B
    Diabetes; 1974 Sep; 23(9):754-62. PubMed ID: 4606797
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the inhibitory effects of propargylamine and pargyline on brain and liver monoamine oxidase activity.
    Abeles RH; Tashjian AH
    Biochem Pharmacol; 1975 Jan; 24(2):307-8. PubMed ID: 1111545
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacological research on pargyline. I. Pressor action and tissue concentrations of catecholamine after administration of single doses].
    Baldieri M
    Arch Ital Sci Farmacol; 1965; 15(3):144-54. PubMed ID: 5877515
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of ACTH1-24 and ACTH4-10 on distribution of 3H-noradrenaline in the brain of adrenalectomized rats.
    Endröczi E
    Acta Physiol Acad Sci Hung; 1976; 48(1):59-64. PubMed ID: 203166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective inhibition of cholinergic receptor-mediated 45Ca++ uptake and catecholamine secretion from adrenal chromaffin cells by taxol and vinblastine.
    McKay DB; Schneider AS
    J Pharmacol Exp Ther; 1984 Oct; 231(1):102-8. PubMed ID: 6149300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Soluble and membrane-bound pig liver mitochondrial monoamine oxidase: thermostability, tryptic digestability and kinetic properties.
    Oreland L; Ekstedt B
    Biochem Pharmacol; 1972 Sep; 21(18):2479-88. PubMed ID: 4646794
    [No Abstract]   [Full Text] [Related]  

  • 16. The fluorescent labeling of mitochondrial monoamine oxidase.
    Rando RR
    Mol Pharmacol; 1977 Jul; 13(4):726-34. PubMed ID: 887076
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanisms of La3+-induced adrenal catecholamine release.
    Bresnahan SJ; Baugh LE; Borowitz JL
    Res Commun Chem Pathol Pharmacol; 1980 May; 28(2):229-44. PubMed ID: 7394322
    [No Abstract]   [Full Text] [Related]  

  • 18. Microassay for the estimation of monoamine oxidase activity.
    Wu PH; Dyck LE
    Anal Biochem; 1976 May; 72():637-42. PubMed ID: 942080
    [No Abstract]   [Full Text] [Related]  

  • 19. Dose-response effects of beta-phenylethylamine on stereotyped behavior in pargyline-pretreated rats.
    Moja EA; Stoff DM; Gillin JC; Wyatt RJ
    Biol Psychiatry; 1976 Dec; 11(6):731-42. PubMed ID: 1033771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the absolute concentrations of monoamine oxidase A and B in human tissues.
    O'Carroll AM; Anderson MC; Tobbia I; Phillips JP; Tipton KF
    Biochem Pharmacol; 1989 Mar; 38(6):901-5. PubMed ID: 2495009
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.